120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
用于银屑病治疗的纳米载体：来自全球临床试验注册平台一项已注册临床试验的见解
Authors Tang S, Xiao R , Zeng Z, Xi J
Received 12 October 2025
Accepted for publication 14 January 2026
Published 11 February 2026 Volume 2026:21 573779
DOI https://doi.org/10.2147/IJN.S573779
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Dong Wang
Shiyang Tang,1 Renzhong Xiao,2,3 Zhaowu Zeng,3 Jianyuan Xi4
1Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China; 2Jinan University, Guangzhou, Guangdong Province, People’s Republic of China; 3Research and Development Department, Hunan Royal Pharmaceutical Technology Co., Ltd., Changsha, Hunan Province, People’s Republic of China; 4The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China
Correspondence: Renzhong Xiao, Jinan University, Guangzhou, Guangdong Province, People’s Republic of China, Email jimmy841228@163.com Jianyuan Xi, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China, Email xijianyuan2010@126.com
Abstract: Psoriasis is a chronic, relapsing inflammatory skin disease. Topical treatments are the primary choice for up to 80% of psoriasis patients; however, their effectiveness is often limited by poor penetration into the skin. Nanocarriers represent a promising advancement in drug delivery systems by enhancing bioavailability and tissue penetration and reducing the frequency of dosing. This study conducted a narrative review and analyzed the characteristics of clinical trials registered on ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) that investigated the use of nanocarriers for psoriasis treatment. The findings indicate that the proportion of registered randomized controlled trials (RCTs) focusing on nanocarriers for psoriasis treatment is exceedingly limited, comprising only 0.2% (11 out of 5338) of all registered RCTs related to psoriasis treatment. Among these 11 RCTs, six types of nanocarriers were identified: microemulsion/nanoemulsion, chitosan nanoparticles, liposomes, ethosomes, micelles, and niosomes. Five trials reported complete or partial outcomes using the Psoriasis Area and Severity Index (PASI) as the primary efficacy measure. However, many trials had incomplete baseline and follow-up PASI data. Studies have shown that encapsulating APIs within nanocarriers generally yields a more significant reduction in PASI scores than administering empty nanocarriers. Additionally, no study has directly compared nanocarriers with traditional formulations. The APIs used in these RCTs primarily comprised lipophilic drugs. In conclusion, although nanocarriers for psoriasis treatment demonstrate significant potential, they continue to face challenges, including incomplete regulatory frameworks, difficulties in large-scale production, and high production costs.
Keywords: psoriasis, nanocarriers, topical drug delivery, clinical trials, ClinicalTrials.gov, liposomes, nanoparticles
1Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China; 2Jinan University, Guangzhou, Guangdong Province, People’s Republic of China; 3Research and Development Department, Hunan Royal Pharmaceutical Technology Co., Ltd., Changsha, Hunan Province, People’s Republic of China; 4The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China
Correspondence: Renzhong Xiao, Jinan University, Guangzhou, Guangdong Province, People’s Republic of China, Email jimmy841228@163.com Jianyuan Xi, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, People’s Republic of China, Email xijianyuan2010@126.com
Abstract: Psoriasis is a chronic, relapsing inflammatory skin disease. Topical treatments are the primary choice for up to 80% of psoriasis patients; however, their effectiveness is often limited by poor penetration into the skin. Nanocarriers represent a promising advancement in drug delivery systems by enhancing bioavailability and tissue penetration and reducing the frequency of dosing. This study conducted a narrative review and analyzed the characteristics of clinical trials registered on ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) that investigated the use of nanocarriers for psoriasis treatment. The findings indicate that the proportion of registered randomized controlled trials (RCTs) focusing on nanocarriers for psoriasis treatment is exceedingly limited, comprising only 0.2% (11 out of 5338) of all registered RCTs related to psoriasis treatment. Among these 11 RCTs, six types of nanocarriers were identified: microemulsion/nanoemulsion, chitosan nanoparticles, liposomes, ethosomes, micelles, and niosomes. Five trials reported complete or partial outcomes using the Psoriasis Area and Severity Index (PASI) as the primary efficacy measure. However, many trials had incomplete baseline and follow-up PASI data. Studies have shown that encapsulating APIs within nanocarriers generally yields a more significant reduction in PASI scores than administering empty nanocarriers. Additionally, no study has directly compared nanocarriers with traditional formulations. The APIs used in these RCTs primarily comprised lipophilic drugs. In conclusion, although nanocarriers for psoriasis treatment demonstrate significant potential, they continue to face challenges, including incomplete regulatory frameworks, difficulties in large-scale production, and high production costs.
Keywords: psoriasis, nanocarriers, topical drug delivery, clinical trials, ClinicalTrials.gov, liposomes, nanoparticles